fiorcet generic ultram wellbutrin zoloft
Comparative Table for Ultram Prices
WOODCLIFF LAKE, N. J., October 14, 2008 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.today announced a resizing of its generic unit as part of an ongoing strategic assessment of its businesses. This initiative will enable Par to more effectively optimize its current product portfolio and its strong pipeline of first-to-file/first-to-market products. As a result, the Company believes it will be better positioned to compete more profitably and efficiently in the generic marketplace over the long term. Par will significantly reduce its research and development (R&D) expenses by decreasing its internal R&D effort to focus on completing products currently in development and will continue to look for opportunities with external partners. The Company will trim its current generic product portfolio retaining only those marketed products that deliver acceptable profit to Par. Patrick G.
Next partM2 PRESSWIRE-19 June 2007-Biotech News: Investor Alert for Pfizer Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:19062007 Pfizer pfabricates pfarmaceuticals pfor quite a pfew inpfirmities. The company is the world's largest research-based pharmaceuticals firm. Its best-known products include erectile dysfunction therapy Viagra, pain management drug Celebrex, antidepressant Zoloft, and cholesterol-lowering Lipitor. Related Results
Venerable brand earns loyalty.(Cough/Cold).(Brief Article)
New Benadryl[R] One A Day Relief to drive sales in grocery no one-a-day aller...
HAYWARD, Calif.-- IMPAX Laboratories, Inc.(NASDAQ:IPXL) today announced that Biovail Laboratories Inc., a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), has filed a lawsuit against the Company in the United States District Court, Eastern District of Pennsylvania (Philadelphia), alleging patent infringement related to IMPAX's filing for a generic version of Wellbutrin XL(R). IMPAX has submitted its filing with the U. S. Food and Drug Administration (FDA) under Paragraph IV of the Hatch-Waxman Amendments, stating that it believes its generic versions of Wellbutrin XL 150 and 300 mg tablets do not infringe Biovail's listed patents or that the listed patents are invalid or unenforceable. Related Results
Wellbutrin approvalWellbutrin disputeWellbutrin XLExtended-release WellbutrinExtended-release Wellbutrin
GlaxoSmithKline markets Wellbutrin XL and for the treatment of depression.